Pink SheetThe US Food and Drug Administration’s review of Mesoblast ’s Ryoncil (remestemcel-L-rknd) shows the agency can change its mind about the quantum of clinical data for a rare disease therapeutic applic
In VivoBioBytes presents an overview of select AI-focused M&As, partnerships and financings in the biopharma industry in Q1 2025. Of note are a $915m alliance between Incyte and Genesis Therapeutics and
Pink SheetA single-arm study cannot provide interpretable results supporting promotional claims for progression-free survival or overall survival, the US Food and Drug Administration said in an advertising and
ScripEquillium is hoping that unmet medical need and long-term efficacy will persuade the US Food and Drug Administration to approve itolizumab for acute graft-versus-host disease (aGVHD) despite its Phase